Business
Atara Biotherapeutics Provides Update in Context of COVID-19 Pandemic
SOUTH SAN FRANCISCO--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company
About this update from Atara Biotherapeutics, Inc.
[{"type":"text","content":" SOUTH SAN FRANCISCO--(BUSINESS WIRE)--\nAtara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today provided an update in context of the COVID-19 (coronavirus) pandemic.\n\n\n“While this is an unprecedented time in history, Atara is working hard to ensure operational continuity to serve patients whose lives are affected by severe diseases,” said Pascal Touchon, President and Chief Executive Officer of Atara Biotherapeutics. “The COVID-19 pandemic is evolving rapidly, and we are closely monitoring it to both ensure the safety and well-being of our employees, patients and communities as well as assess the potential impacts to our business so we can continue delivering transformative medicines to patients in critical need.”\n\n\nTab-cel®:\n\n\nAtara believes that it remains on track to initiate a tab-cel® biologics license application (BLA) submission for patients with EBV+ PTLD in the second half of 2020. While clinical study operations and the opening of additional Phase 3 study sites in U.S., Canada and Europe have been impacted by the spread of COVID-19, at this time most sites remain open to enrollment for patients with this life-threatening condition who have no other approved therapeutic options.\n\n\nATA188 for Multiple Sclerosis (MS):\n\n\nWe continue to monitor patients in our Phase 1a clinical study of off-the-shelf, allogeneic ATA188 in patients with progressive MS across clinical sites in the U.S. and Australia. Atara expects to present in an appropriate forum the ATA188 Phase 1a six-month clinical results for cohorts 1-4 and 12-month results for cohorts 1-3 in Q2 2020. We are also allowing for re-treatment in the open-label extension (OLE) of the Phase 1a in an appropriate setting and as determined by the treating physician and patient. We have decided to temporarily pause the screening and enrollment of patients in our Phase 1b randomized controlled study to ensure sites can focus on meeting the needs of patients with COVID-19 and to protect the safety of study participants, investigators, and staff. This will also help preserve the study and data integrity as there are numerous assessments that require a specific clinical setting.\n\n\nOperations:\n\n\nAtara continues to delive...